A signature-based method for indexing cell cycle phase distribution from microarray profiles

BackgroundThe cell cycle machinery interprets oncogenic signals and reflects the biology of cancers. To date, various methods for cell cycle phase estimation such as mitotic index, S phase fraction, and immunohistochemistry have provided valuable information on cancers (e.g. proliferation rate). However, those methods rely on one or few measurements and the scope of the information is limited. There is a need for more systematic cell cycle analysis methods.ResultsWe developed a signature-based method for indexing cell cycle phase distribution from microarray profiles under consideration of cycling and non-cycling cells. A cell cycle signature masterset, composed of genes which express preferentially in cycling cells and in a cell cycle-regulated manner, was created to index the proportion of cycling cells in the sample. Cell cycle signature subsets, composed of genes whose expressions peak at specific stages of the cell cycle, were also created to index the proportion of cells in the corresponding stages. The method was validated using cell cycle datasets and quiescence-induced cell datasets. Analyses of a mouse tumor model dataset and human breast cancer datasets revealed variations in the proportion of cycling cells. When the influence of non-cycling cells was taken into account, "buried" cell cycle phase distributions were depicted that were oncogenic-event specific in the mouse tumor model dataset and were associated with patients' prognosis in the human breast cancer datasets.ConclusionThe signature-based cell cycle analysis method presented in this report, would potentially be of value for cancer characterization and diagnostics.

[1]  K. Jabboury,et al.  Cell proliferation kinetics of normal and tumour tissue in vitro: quiescent reproductive cells and the cycling reproductive fraction , 1995, Cell proliferation.

[2]  Terence P. Speed,et al.  A comparison of normalization methods for high density oligonucleotide array data based on variance and bias , 2003, Bioinform..

[3]  Itaru Matsumura,et al.  Cell cycle regulation in hematopoietic stem/progenitor cells. , 2004, Cell cycle.

[4]  M. Ikawa,et al.  Lats2 Is an Essential Mitotic Regulator Required for the Coordination of Cell Division* , 2007, Journal of Biological Chemistry.

[5]  Yudong D. He,et al.  Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.

[6]  Hongjuan Zhao,et al.  TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer , 2007, Breast Cancer Research.

[7]  D. Bryder,et al.  Prolonged Cell Cycle Transit Is a Defining and Developmentally Conserved Hemopoietic Stem Cell Property1 , 2006, The Journal of Immunology.

[8]  C. Ball,et al.  Identification of genes periodically expressed in the human cell cycle and their expression in tumors. , 2002, Molecular biology of the cell.

[9]  C Sotiriou,et al.  Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now? , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  B. N. Day,et al.  Cell cycle analysis of cultured porcine mammary cells. , 1999, Cloning.

[11]  J. Harper,et al.  The mammalian cell cycle: an overview. , 2005, Methods in molecular biology.

[12]  S. Ng,et al.  Ras transformation results in an elevated level of cyclin D1 and acceleration of G1 progression in NIH 3T3 cells , 1995, Molecular and cellular biology.

[13]  Andreas Makris,et al.  Measuring proliferation in breast cancer: practicalities and applications , 2006, Breast Cancer Research.

[14]  Jeffrey T. Chang,et al.  Oncogenic pathway signatures in human cancers as a guide to targeted therapies , 2006, Nature.

[15]  K. Stoeber,et al.  Cell cycle markers in clinical oncology. , 2007, Current opinion in cell biology.

[16]  H. Dressman,et al.  Genomic signatures to guide the use of chemotherapeutics , 2006, Nature Medicine.

[17]  G. Williams,et al.  DNA replication licensing and cell cycle kinetics of normal and neoplastic breast , 2005, British Journal of Cancer.

[18]  R. Young,et al.  A common set of gene regulatory networks links metabolism and growth inhibition. , 2004, Molecular cell.

[19]  M. Bissell,et al.  Interaction with basement membrane serves to rapidly distinguish growth and differentiation pattern of normal and malignant human breast epithelial cells. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[20]  Zhiyuan Hu,et al.  Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors , 2007, Genome Biology.

[21]  D. Felsher,et al.  Transient excess of MYC activity can elicit genomic instability and tumorigenesis. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[22]  C. Croce,et al.  Fez1/Lzts1 a new mitotic regulator implicated in cancer development , 2007, Cell Division.

[23]  M. Bissell,et al.  Gene expression signature in organized and growth-arrested mammary acini predicts good outcome in breast cancer. , 2006, Cancer research.

[24]  Pierre R. Bushel,et al.  Profiles of Global Gene Expression in Ionizing-Radiation–Damaged Human Diploid Fibroblasts Reveal Synchronization behind the G1 Checkpoint in a G0-like State of Quiescence , 2005, Environmental health perspectives.

[25]  I. Simon,et al.  Genome-wide transcriptional analysis of the human cell cycle identifies genes differentially regulated in normal and cancer cells , 2008, Proceedings of the National Academy of Sciences.

[26]  Alok J. Saldanha,et al.  Java Treeview - extensible visualization of microarray data , 2004, Bioinform..

[27]  Aleksey A. Nakorchevskiy,et al.  Expression deconvolution: A reinterpretation of DNA microarray data reveals dynamic changes in cell populations , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[28]  S. J. Marriott,et al.  Accelerated G1 Phase Progression Induced by the Human T Cell Leukemia Virus Type I (HTLV-I) Tax Oncoprotein* , 2001, The Journal of Biological Chemistry.

[29]  Joshy George,et al.  Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. , 2006, Cancer research.

[30]  T. Sladek,et al.  Simian virus 40 large T-antigen expression decreases the G1 and increases the G2 + M cell cycle phase durations in exponentially growing cells , 1992, Journal of virology.

[31]  Michael A. Gonzalez,et al.  Geminin predicts adverse clinical outcome in breast cancer by reflecting cell‐cycle progression , 2004, The Journal of pathology.

[32]  Gavin D. Grant,et al.  Common markers of proliferation , 2006, Nature Reviews Cancer.

[33]  Miki Ebisuya,et al.  Continuous ERK Activation Downregulates Antiproliferative Genes throughout G1 Phase to Allow Cell-Cycle Progression , 2006, Current Biology.

[34]  F. C. Lucibello,et al.  Inducible acceleration of G1 progression through tetracycline-regulated expression of human cyclin E. , 1994, Oncogene.

[35]  G Landberg,et al.  The cell cycle in breast cancer , 1997, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[36]  H. Wu,et al.  PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3,4,5,-trisphosphate and Akt/protein kinase B signaling pathway. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[37]  J. Karn,et al.  Regulation of cell cycle duration by c-myc levels. , 1989, Oncogene.

[38]  D. Barnes,et al.  Cyclin D1 in Breast Cancer , 2004, Breast Cancer Research and Treatment.